Q2 EPS Estimate for Agios Pharmaceuticals Boosted by Analyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Investment analysts at Zacks Research boosted their Q2 2025 earnings per share estimates for shares of Agios Pharmaceuticals in a report released on Thursday, May 22nd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of ($1.77) for the quarter, up from their prior estimate of ($1.82). The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share. Zacks Research also issued estimates for Agios Pharmaceuticals' Q3 2025 earnings at ($1.89) EPS, Q4 2025 earnings at ($2.05) EPS, FY2025 earnings at ($7.25) EPS, Q1 2026 earnings at ($1.65) EPS, Q2 2026 earnings at ($1.73) EPS, Q3 2026 earnings at ($1.80) EPS, Q4 2026 earnings at ($1.90) EPS, FY2026 earnings at ($7.09) EPS, Q1 2027 earnings at ($1.56) EPS and FY2027 earnings at ($6.70) EPS.

A number of other equities analysts also recently issued reports on AGIO. HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price target on the stock. Scotiabank dropped their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 2nd. Finally, Wall Street Zen downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $56.00.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock traded up $0.63 on Monday, reaching $30.83. The stock had a trading volume of 531,184 shares, compared to its average volume of 694,159. The stock has a market cap of $1.79 billion, a P/E ratio of 2.72 and a beta of 0.77. Agios Pharmaceuticals has a 1 year low of $23.42 and a 1 year high of $62.58. The company has a 50 day simple moving average of $28.57 and a 200 day simple moving average of $35.67.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. The firm had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after buying an additional 85,339 shares in the last quarter. Erste Asset Management GmbH lifted its stake in shares of Agios Pharmaceuticals by 10.9% during the 1st quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company's stock valued at $65,439,000 after buying an additional 220,000 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at $49,290,000. Frazier Life Sciences Management L.P. lifted its stake in Agios Pharmaceuticals by 2.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company's stock worth $35,152,000 after purchasing an additional 25,600 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its stake in Agios Pharmaceuticals by 12.3% in the 4th quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock worth $31,567,000 after purchasing an additional 105,333 shares in the last quarter.

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the transaction, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. The trade was a 4.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.